Ihre
gewählte
Nachricht : |
|
| Datum : | 14.05.2014 |
Titel : |
DGAP-News: Willkie Farr & Gallagher LLP: Willkie advises RIEMSER Pharma on takeover of Keocyt, a French pharmaceutical company |
| Meldung : | DGAP-News: Willkie Farr & Gallagher LLP / Key word(s): Acquisition/Acquisition Willkie Farr & Gallagher LLP: Willkie advises RIEMSER Pharma on takeover of Keocyt, a French pharmaceutical company 14.05.2014 / 16:22 --------------------------------------------------------------------- German specialty pharmaceutical company RIEMSER Pharma GmbH today announced the acquisition of French specialty pharmaceutical company Keocyt. With this acquisition, RIEMSER reached another important milestone of its international growth strategy and significantly strengthens its position on the French and neighbouring Southern European markets. Keocyt brings to market pharmaceutical products that are applied in the treatment of rare diseases, especially in cancer therapy and neurology. The Paris based company was founded in 2007 by two former employees of Pfizer and markets the drugs Zanosar, Estracyt, Prodilantin and Dilantin used for the treatment of certain pancreatic endocrine tumors, prostate cancer and status epilepticus, respectively. "I am very pleased that with the backing of our majority shareholder ARDIAN, we could acquire Keocyt, a very successful specialty pharmaceutical company, to further strengthen our European growth strategy. The course of the acquisition of companies with established products and strong marketing expertise we want to continue, "said Dr. Kai Deusch, CEO of RIEMSER Pharma GmbH. "This acquisition successfully ex-tends our oncological portfolio in France and opens possibilities of developing niche markets in the neurological sector in the future. In addition, Keocyt contributes a very attractive product pipeline to the joint cohesive product portfolio." "We are very excited about the opportunity to jointly expand and accelerate our growth strategy in the French and Southern European markets under the roof of RIEMSER Pharma GmbH", said Dr. Christophe Pasik, co-founder of Keocyt, who will serve as the CEO of RIEMSER Pharma France S.A.S which will have its headquarters in Paris. Willkie Farr & Gallagher LLP provided legal counsel to RIEMSER Pharma GmbH. The Willkie team was led by Mario Schmidt (Corporate/Private Equity, Frankfurt) and Eduardo Fernandez (Corporate, Paris) and included the partners, Jan Wilms (Finance, Frankfurt), Special European Counsel Karine Lenczner (Corporate, Paris), National Partner Paul Lombard (Public Law and Financing, Paris) and the associates Alexandre Avrillon (Corporate, Paris), Mario Bammann (Finance, Frankfurt), Mariele Coulet Diaz (Corporate, Paris), Tobias Daubert (Finance, Frankfurt), Claire de Bonnieres (Corporate, Paris), Igor Kukhta (Corporate, Paris), Xavier Nassoy (Corporate, Paris) and Daniel Zakrewski (Corporate/Private Equity, Frankfurt). Willkie Farr & Gallagher LLP is an international law firm, comprising more than 600 attorneys with offices in New York, Washington, Paris, London, Milan, Rome Frankfurt and Brussels. The headquarters are in New York, 787 Seventh Avenue, Tel.: 001 212 728 8000. Frankfurt, May 13, 2014 End of financial news --------------------------------------------------------------------- 14.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------- 268483 14.05.2014 |
| Sender : | Homepage |